Kamada (NASDAQ:KMDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com started coverage on shares of Kamada (NASDAQ:KMDA) in a research report sent to investors on Wednesday morning. The firm issued a buy rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, May 9th.

Kamada Price Performance

Shares of KMDA opened at $5.06 on Wednesday. The company has a market capitalization of $290.85 million, a PE ratio of 22.00 and a beta of 1.06. Kamada has a one year low of $4.08 and a one year high of $6.53. The company’s fifty day moving average price is $5.28 and its 200 day moving average price is $5.66.

Kamada (NASDAQ:KMDA) last announced its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.06 by ($0.02). The company had revenue of $37.74 million for the quarter, compared to analyst estimates of $38.01 million. Kamada had a net margin of 8.33% and a return on equity of 5.50%. Analysts anticipate that Kamada will post 0.26 earnings per share for the current year.

Institutional Trading of Kamada

Several large investors have recently added to or reduced their stakes in the company. EWA LLC acquired a new position in shares of Kamada during the fourth quarter worth approximately $68,000. Y.D. More Investments Ltd raised its holdings in Kamada by 107.1% in the fourth quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock worth $177,000 after purchasing an additional 15,000 shares during the period. Calton & Associates Inc. acquired a new stake in Kamada in the fourth quarter worth $111,000. Aristides Capital LLC raised its holdings in Kamada by 41.6% in the fourth quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 16,635 shares during the period. Finally, Vanguard Group Inc. increased its position in shares of Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after acquiring an additional 100,800 shares in the last quarter. 20.38% of the stock is owned by institutional investors.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.